Treatment of Gonorrhoea with Ertapenem: Evidence-Based Protocol

Clinical Scenario

This protocol covers gonorrhoea cases in which ertapenem is the indicated treatment. The evidence base includes both real-world use in difficult-to-treat infections and data from a randomised controlled trial evaluating intramuscular administration.

Treatment Approach

Treatment is centred on ertapenem delivered parenterally. Both intravenous and intramuscular routes are addressed in the protocol, with distinct evidence supporting each. Full dosing specifications, duration, and route selection criteria are defined in the structured regimen.

Complete regimen details available in the full protocol ↓

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/09564624251345195

Some infections with MDR N. gonorrhoeae have been successfully treated with ertapenem when ceftriaxone has failed; three days of IV ertapenem 1 g was used for these cases, although this was a pragmatic choice and not guided by clinical trial data.
In a recent RCT, a single 1 g dose of ertapenem IM was noninferior to ceftriaxone 500 mg IM, although all strains were susceptible to ceftriaxone and had low ertapenem MICs.

View source ↗